Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temelimab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ProTEct-MS
  • Sponsors GeNeuro

Most Recent Events

  • 13 Oct 2023 Results assessing paramagnetic rim lesions with soluble biomarker/imaging profiles and clinical features in a cohort of people with relapsing forms of MS (pwMS) with clinical worsening despite antiCD20 therapy presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
  • 05 Apr 2023 According to a GeNeuro media release, ProTEct-MS study was performed in Stockholm, Sweden, at the Karolinska Institutet's Academic Specialist Center in Stockholm under the leadership of Prof. Fredrik Piehl.
  • 28 Oct 2022 Primary endpoint (Safety and tolerability: adverse event) has been met according to results presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top